Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
CONCLUSION: The IIV4 and PPV23 can be co-administered without reducing antibody responses reflecting protection against influenza or pneumococcal disease. Co-administration of PPV23 at the annual influenza vaccination visit may improve uptake. Comorbidities had no impact on IIV4 immunogenicity, supporting its value in older adults with chronic medical conditions. Clinical Trial Registry Number: NCT02218697.
PMID: 28987445 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL Tags: Vaccine Source Type: research
More News: Belgium Health | Brain | Cardiology | Chronic Pain | Clinical Trials | Diabetes | Eating Disorders & Weight Management | Endocrinology | Eyes | France Health | Heart | Influenza | Influenza Vaccine | Liver | Meningitis Vaccine | Neurology | Obesity | Pain | Pneomococcal Vaccine | Respiratory Medicine | Study | Urology & Nephrology | Vaccines